Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/f10d86b7-9f9e-4997-975e-dff8ee5ad1d7/

DARE

Dare Bioscience Inc
Chart
$1.88
Latest Week 2026-06-05
HealthcareBiotechnologyNANO
Snapshot 2026-06-07 · 0.0w · Fresh
0.63
OS Score
55.0%
Value
55.0%
Quality
55.0%
Momentum
4/9
F-Score
0.550
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
0 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
55.0%ile
P/S
23.6×
P/B
37.2×
FCF Yield
-0.941
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
45.00000000
/100 — 1=cheapest
VC2 (Trending Value)
45.00000000
/100
VC3 (Buyback)
45.00000000
/100
Negative FCF yield (-94.1%) — the business is currently cash-consumptive.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
55.0%ile
ROE
-16.367
ROA
-0.432
Net Margin
-10.388
Op Margin
-10.344
GPA
0.002
D/E
36.89
Current
1.03
F-Score
4/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Stability
3.523
lower=better
Accruals
-0.075
lower=better
5yr Consist
No
Highly leveraged with D/E of 36.89 — returns are being amplified by debt.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
55.0%ile
6M Return
5.6%
12M Return
-41.2%
12-1 Mom
-14.1%
Risk-Adj
-0.14
Vol 252d
100.6%
Vol 60d
242.4%
↑ Expanding
Max DD 12M
-55.1%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of -14% signals a downtrend — price is moving against you. Near-term vol (242%) is expanding vs long-term (101%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.63
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
47.1%
Sector Quality %ile
49.7%
P/B z-score
2.71
Sector Avg OS
63.3%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
IRWD Ironwood Pharmaceuticals Inc 99.0% 93.0% 86.0% 98.0%
FBIO Fortress Biotech Inc 98.0% 97.0% 93.0% 74.0%
RIGL Rigel Pharmaceuticals Inc 98.0% 94.0% 92.0% 76.0%
CGEN Compugen 97.0% 90.0% 95.0% 76.0%
WW WW International, Inc. Common Stock 97.0% 88.0% 80.0% 99.0%
FBIOP Fortress Biotech Inc Pref Series A 97.0% 81.0% 95.0% 90.0%
PBYI Puma Biotechnology Inc 97.0% 80.0% 97.0% 92.0%
MD Mednax Inc 96.0% 87.0% 80.0% 87.0%
Factor Interactions
Volatility Expanding
60-day vol (242%) significantly exceeds 252-day (101%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
F
2.8% avg (4 factors)
Quality
F
13.9% avg (8 factors)
Momentum
F
20.1% avg (4 factors)
Risk
F
0.0% avg (1 factors)
Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required. Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.630—0—
Value %ile0.550—0—
Quality %ile0.550—0—
Momentum %ile0.550—0—
F-Score4.000—1—
Confidence0.818—1—
Volatility1.006—1—
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
Price / Sales
23.59
Price / Book
37.17
FCF Yield
-94.1%
Sales Yield (1/P·S)
0.1158
Shareholder Yield
Div + net buyback / mktcap
0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
-1636.7%
Return on Assets
-43.2%
Net Margin
-1038.8%
Operating Margin
-1034.4%
Gross Profit / Assets
Novy-Marx GPA
0.2%
Debt / Equity
36.89
Current Ratio
1.03
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.075
MomentumPrice trend strength over different horizons
6M Return
5.6%
12M Return
-41.2%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
-14.1%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
-0.14
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Earnings Stability (CV)
Lower = more stable
3.523
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
4
Dividend Yield
0.0%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
45
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
45
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
45
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity